{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T04:20:05Z","timestamp":1787631605479,"version":"build-2736575974"},"reference-count":30,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2022,11,13]],"date-time":"2022-11-13T00:00:00Z","timestamp":1668297600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004097","name":"Fondation ARC pour la Recherche sur le Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004097","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004099","name":"Ligue Contre le Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004099","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004097","name":"Fondation ARC pour la Recherche sur le Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004097","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:sec><jats:title>Aims<\/jats:title><jats:p>Pharmacovigilance signals of heart failure (HF) following exposure to protein kinase inhibitors (PKIs) have been detected in recent years. Our aim was to identify the PKIs most frequently associated with the development of HF.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Using the French National Healthcare Database, all patients newly exposed to a PKI between January 2011 and June 2014 were followed up for 18\u2009months. Specific hospitalization diagnosis and long\u2010term HF\u2010related disease codes were used to identify HF patients. HF incidence rate ratios (IRRs) were measured and adjusted hazard ratios (aHRs) were estimated using a Cox model. Sensitivity analyses were performed to limit the potential indication and competitive risk bias.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Thirteen PKIs were studied. Among the 49\u2009714 new PKI users registered during the study period, the mean IRR of HF was 3.38 per 100 person\u2010years, with a median time to onset of 155\u2009days. We found a significant increase in the incidence of HF for six medicinal products: pazopanib (aHR\u2009=\u20092.42, 95% confidence interval [CI] 1.67\u20103.52), dasatinib (aHR\u2009=\u20092.22, 95% CI 1.42\u20103.44), ruxolitinib (aHR\u2009=\u20092.11, 95% CI 1.69\u20102.64), crizotinib (aHR\u2009=\u20091.71, 95% CI 1.07\u20102.72), everolimus (aHR\u2009=\u20091.45, 95% CI 1.26\u20101.67) and vemurafenib (aHR\u2009=\u20091.37, 95% CI 1.01\u20101.86). Sensitivity analyses were consistent with our primary analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The current study provides knowledge on HF following exposure to a PKI. Additional studies could confirm these results for dasatinib, everolimus, pazopanib and ruxolitinib, and particularly for the two medicinal products with results slightly above the significance threshold, namely, crizotinib and vemurafenib, in our sensitivity analyses.<\/jats:p><\/jats:sec>","DOI":"10.1111\/bcp.15576","type":"journal-article","created":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T08:23:25Z","timestamp":1666772605000},"page":"1338-1348","source":"Crossref","is-referenced-by-count":4,"title":["Incidence of heart failure following exposure to a protein kinase inhibitor, a French population\u2010based study"],"prefix":"10.1111","volume":"89","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6289-2567","authenticated-orcid":false,"given":"Yoann","family":"Zelmat","sequence":"first","affiliation":[{"name":"Medical and Clinical Pharmacology Unit University Hospital Centre Toulouse  Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Conte","sequence":"additional","affiliation":[{"name":"Medical and Clinical Pharmacology Unit University Hospital Centre Toulouse  Toulouse France"},{"name":"Department of Medical and Clinical Pharmacology, Centre of PharmacoVigilance and Pharmacoepidemiology Toulouse University Hospital, Faculty of Medicine  Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pernelle","family":"Noize","sequence":"additional","affiliation":[{"name":"Bordeaux University, INSERM, BPH, U1219  Bordeaux France"},{"name":"Department of Medical and Clinical Pharmacology Bordeaux University Hospital  Bordeaux France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9mentine","family":"Vabre","sequence":"additional","affiliation":[{"name":"Medical and Clinical Pharmacology Unit University Hospital Centre Toulouse  Toulouse France"},{"name":"Department of Medical and Clinical Pharmacology, Centre of PharmacoVigilance and Pharmacoepidemiology Toulouse University Hospital, Faculty of Medicine  Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Pajiep","sequence":"additional","affiliation":[{"name":"Medical and Clinical Pharmacology Unit University Hospital Centre Toulouse  Toulouse France"},{"name":"Department of Medical and Clinical Pharmacology, Centre of PharmacoVigilance and Pharmacoepidemiology Toulouse University Hospital, Faculty of Medicine  Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6010-2891","authenticated-orcid":false,"given":"Margaux","family":"Lafaurie","sequence":"additional","affiliation":[{"name":"Medical and Clinical Pharmacology Unit University Hospital Centre Toulouse  Toulouse France"},{"name":"Department of Medical and Clinical Pharmacology, Centre of PharmacoVigilance and Pharmacoepidemiology Toulouse University Hospital, Faculty of Medicine  Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5494-5873","authenticated-orcid":false,"given":"Maryse","family":"Lapeyre\u2010Mestre","sequence":"additional","affiliation":[{"name":"Medical and Clinical Pharmacology Unit University Hospital Centre Toulouse  Toulouse France"},{"name":"Department of Medical and Clinical Pharmacology, Centre of PharmacoVigilance and Pharmacoepidemiology Toulouse University Hospital, Faculty of Medicine  Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabien","family":"Despas","sequence":"additional","affiliation":[{"name":"Medical and Clinical Pharmacology Unit University Hospital Centre Toulouse  Toulouse France"},{"name":"Department of Medical and Clinical Pharmacology, Centre of PharmacoVigilance and Pharmacoepidemiology Toulouse University Hospital, Faculty of Medicine  Toulouse France"},{"name":"Clinical Investigation Centre 1436 University Hospital Centre Toulouse  Toulouse cedex 9 France"},{"name":"Equipe Pharmacologie en Population (Population Pharmacology Team), cohorteS, biobanqueS, PEPPS Toulouse University  Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,11,13]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41573\u2010021\u201000195\u20104"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609324"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j4530"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.therap.2018.08.001"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.24406"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.therap.2021.08.001"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1701"},{"key":"e_1_2_10_9_1","unstructured":"Epidemiology of heart failure in France from the national public health agency (\"Sant\u00e9 Publique France\"). Accessed June 21 2021.https:\/\/www.santepubliquefrance.fr\/maladies-et-traumatismes\/maladies-cardiovasculaires-et-accident-vasculaire-cerebral\/insuffisance-cardiaque"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.acvd.2014.01.012"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13238"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1177\/1078155219875797"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1136\/bcr\u20102018\u2010225613"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/bcr\u20102015\u2010211522"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.37616\/2212\u20105043.1125"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn168"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.6331"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000426"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp100637"},{"key":"e_1_2_10_20_1","unstructured":"M\u00e9thodologie m\u00e9dicale de la cartographie des pathologies et des d\u00e9penses version G7 (ann\u00e9es 2012E \u00e0 2018). Accessed March 4 2021.https:\/\/www.ameli.fr\/fileadmin\/user_upload\/documents\/Methodologie_medicale_cartographie.pdf"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12874\u2010020\u20100914\u20106"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471\u20102458\u20109\u201033"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4233"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2012.09.017"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1858"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.592"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2017.88"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrcardio.2015.65"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23052815"},{"key":"e_1_2_10_30_1","unstructured":"French National Healthcare Data System (Syst\u00e8me National des Donn\u00e9es de Sant\u00e9 SNDS). Accessed June 21 2021.https:\/\/www.snds.gouv.fr\/"},{"key":"e_1_2_10_31_1","unstructured":"Bosco\u2010L\u00e9vyP.Heart failure in France: chronic heart failure therapeutic management and risk of cardiac decompensation in real\u2010life setting.https:\/\/www.theses.fr\/2013BORD0348"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.15576","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bcp.15576","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.15576","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T20:15:52Z","timestamp":1692648952000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.15576"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,13]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["10.1111\/bcp.15576"],"URL":"https:\/\/doi.org\/10.1111\/bcp.15576","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,13]]}}}